Chinese Medical Journal, Год журнала: 2024, Номер unknown
Опубликована: Дек. 10, 2024
To the Editor: As early as in mid-19th century, microbiologists first recognized multiple microorganisms within human tumors. Nevertheless, perceptions of intratumor microbiome have made little progression during 50 years 20th century owing to contamination interference, experimental irreproducibility, and technical limitations. Strikingly, past decade, advances detection techniques analytical tools been opening unprecedented opportunities widely investigate manifold characteristics low-biomass host–microbe interplays. In second decade 21st researchers focusing on gradually emerged. Initially, this adventurous perspective failed draw much attention because tumors were still considered sterile mainstream belief at that time. realized significant role tumor biology, immunity, metabolism a non-negligent new component microenvironments (TME), soon became hot. Gradually, microbiomes emerged diagnostic prognostic biomarkers, even strenuous endeavors devoted tapping their potential therapeutic targets.[1–5] Yet, it remains left translate microbes-based tumor-specific therapies into clinical practice. Therefore, there is great significance delineating research status evolution trend microbiome. We conducted bibliometric analysis 487 related publications extracted from Web Science Core Collection inception April 11, 2024 [Supplementary Methods Supplementary Figures 1 2, https://links.lww.com/CM9/C186], mapping current landscape hope proffering fresh clues for future research. There blowout annual publications, predictive annual/cumulative are 221 614, respectively, Figure 3, https://links.lww.com/CM9/C186]. Fifty-six countries published documents, wherein less than 20% them contributed more 10 4A Table 1, Most cooperation confined Europe, North America, handful Asian countries/institutions 4B–E, China has leading producer 7 out top productive institutions also held by China. But United States continued dominate field global center with overwhelming citations. This partially recently cut striking figure 4C, E, A total 3505 authors provided 84.9% single publication 5A, Only 489 co-authorship relationships 5B, C, Just Ravid Straussman Jennifer Wargo concurrently among prolific cited Deborah Nejman endowed higher citations H-index but does not possess reflecting his stringent quality control over publications. most co-cited author 5D, The come prominence last couple except distributed discontinuously 2018 2023 5E, Included sourced 232 journals, 14 journals judged core 6A, highest albeit only two Cell possesses link strength despite five whereas Cancers 6B classified 4 clusters 6C, Citing chiefly Molecular/Biology/Immunology Medicine/Medical/Clinical, called frontiers; Molecular/Biology/Genetics, knowledge base 6D, Thirteen documents ranked 20 local citation score (LCS) (GCS) 4, These incipient high LCS proffer theoretical basis subsequent exhaustive study biological functions. 7A, https://links.lww.com/CM9/C186 portrays relationships, while 7B, demonstrates document's impact field. 7C, further shows relationship LCS. 8A, depicts reference co-citation network, forming thorough examinations 8B, highly references since 2015, many continue be 8C 5, hotspots already shifted initial topics (e.g., #12, #17, #21, #23), #0 pancreatic cancer, #1 electroporation, #2 engineered bacteria, #5 microbiome-based therapy, etc., represent hotspots. Especially, therapy including bacteria generated one or years. burst can traced back Grivennikov SI, 2012, Nature, latest took place 2021, attributed Li S, 2017, Microbiome 8D, Notably, Geller LT, experienced strongest burst. Keyword frequency examined word clouds heatmap 9A–C 6, generally evincing emphasis. relatively homogeneous before principally prostate cancer gender; nevertheless, suddenly surged 2021 9D, Specifically, emergence some keywords top-left corner diagnosis, prognosis, biomarker, TME) gained 2 years, discernible shift orientation endeavors, diagnosis prognosis intense interests. Similarly, metastasis, metabolism, immune microenvironment, evolved salient 9E, gut microbiome, enduring recent Colorectal dysbiosis, 16s rRNA belong Motor Themes, denoting they themes maturity 9F, Whereas metastasis belongs Niche indicating well-developed banal. Conversely, Basic demonstrating enough, therefore may become trends. above prefigures trajectories, encompassing therapy. Below, we will elucidate far-reaching meaning realm implications directions. Correlation between microbiome: Gut could main origin directly invade gastrointestinal tissues via impaired mucosa, translocate non-mucosal organs, such pancreas through ducts. Furthermore, given cells immunocytes, transported form fractions intact cell migration. conjectures must validated holistic metagenomic sequencing genetic identification. Apart direct association microbial translocation, remote communication mediates latent connection. indirectly affect TME metabolites system, culminating altering modulate microbiome? Further warranted interplay its effects TME. Tumor immunomodulation: Intratumor reshapes microenvironment (TIME) modulating pro-tumoral antitumor immunity. microecology facilitates recruitment activation counteracts Meanwhile, augments immunity focus activation, exerts inhibitory immunocytes. Although exact mechanisms multitudinous immunomodulation yet elucidated, underlying include (1) valid presentation antigens, especially antigens mimicry shared antigens; (2) microbe-induced immunogenic death; (3) microbe-derived metabolites, (4) pattern recognition receptor-mediated adjuvanticity. Collectively, target supporting immunotherapy, context-dependent require clarification prior translation. It topic facing grand challenges deserves exploration. Metabolic regulation: reprograms convoluted 7, play double-edged sword TIME non-negligible mediators interactions. complicated impacts depend several factors, type, stage, host genotype, specific metabolite, which necessitates study. Targeting metabolic regulation should monumental subject research, comprehensive perception microbe enlighten strategies. Diagnosis prognosis: associated clinicopathological features age, gender, subtypes, histological grade), valuable indicator subtype stratification, staging classification. abundance responses outcomes, promising tool prognosis. Given invasiveness difficulty obtaining tissue samples, accumulating studies typically utilize alternative sputum bronchoalveolar lavage fluid. tumor-associated circulating DNA, biomarker liquid biopsy, Additionally, combining multiple-omics data other emerging sampling techniques, ingestible capsules sampling, favor precise Cancer therapy: multidimensional plays roles determining response antineoplastic therapies. Consequently, targeting adjuvant strategies following points: eliminating detrimental carcinogenic species; fostering beneficial microbiome; metabolite-based intervention reprogram TIME; ameliorate chemotherapy, radiotherapy; (5) microbe-inspired drug delivery. particular, technological development reformed design presents preferential tumors, aggressive penetration, easy recognition, controllable cytotoxicity. genetically release products trigger reactions handicapping function hitchhiking targeted delivery immunostimulators, toxins, drugs. somewhat challenging determine optimal dose dosing schedule live bacterial substances, administration substances risk life-threatening infections sepsis. combine conventional therapies, ideas upgrade efficacy. traditional Chinese medicine successfully applied few report about approach provides experience speculate triangular interaction medicine, microbiota, inevitable limitations Other database-derived non-English omitted. presented temporal limitation. bibliometrics constricted metadata rather full-text analysis. these would alter findings. Overall, visualization explore frontiers According systematical analysis, endows additional multivariate divergent an attractive target. depict microbiome-mediated molecular networks environment. Perhaps eventual destination Funding work was supported National Natural Foundation (No. 82150006), Society Clinical Oncology Research (Nos. Y-HR2017-117, Y-HH202102-0060), Beijing Medical Health YWJKJJHKYJJ-F3046D), Qujiang District Quzhou City Life Oasis Public Service Center BJHA-CRP-040), Wu Jieping 320.6750.2023-05-10) Yawen Gao. Conflicts interest None.
Язык: Английский
